OncoGenex Pharmaceuticals (ACHV) Earns News Impact Score of 0.25

News articles about OncoGenex Pharmaceuticals (NASDAQ:ACHV) have trended positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OncoGenex Pharmaceuticals earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.5770063773149 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news articles that may have effected Accern Sentiment’s rankings:

Separately, ValuEngine upgraded shares of OncoGenex Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th.

Shares of OncoGenex Pharmaceuticals (ACHV) opened at $1.35 on Wednesday. OncoGenex Pharmaceuticals has a 52-week low of $1.29 and a 52-week high of $10.23.

OncoGenex Pharmaceuticals (NASDAQ:ACHV) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.90) EPS for the quarter.

COPYRIGHT VIOLATION NOTICE: This news story was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.chaffeybreeze.com/2017/11/15/oncogenex-pharmaceuticals-achv-earns-news-impact-score-of-0-25.html.

About OncoGenex Pharmaceuticals

Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.

Insider Buying and Selling by Quarter for OncoGenex Pharmaceuticals (NASDAQ:ACHV)

Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply